2025年1月28日 · Kintor Pharmaceutical just announced that its China Phase II clinical trial of its first-in-class androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound GT20029 for treating androgenetic alopecia has reached the primary endpoint. The results are statistically significant and clinically meaningful, while safety and tolerability ...

2023年7月19日 · Kintor Pharmaceutical Ltd. recently announced the US phase II clinical trial results for its androgen receptor antagonist, pyrilutamide. This topical androgen receptor-blocking drug, also known as KX-826, is being developed for the treatment of male and female androgenetic alopecia (pattern hair loss). What Is Pyrilutamide (KX-826) Used for?

2023年3月21日 · GT20029 is a topical AR-Proteolysis Targeting Chimera (PROTAC) owned by Kintor Pharma. In preclinical studies, by degrading AR protein, GT20029 could block the shrinkage and miniaturization of hair follicles which was caused by the activation of AR signaling pathway. As the result, it prevented the hair from thinning, softening and falling out.

The pipeline of potential new treatments for male androgenetic alopecia is strong. Pyrilutamide and GT20029 are being studied as topical antagonists of the androgen receptor, while cetirizine is another topical option with some initial promising results.

2023年2月13日 · The placebo-controlled, parallel-group, randomised, double-blind, dose-escalation Phase I clinical trial assessed GT20029’s tolerability, pharmacokinetics, and safety after topical single ascending dose (SAD) administration in healthy participants and multiple ascending dose administration (MAD) in androgenetic alopecia (AGA) or acne subjects.

The pipeline of potential new treatments for male androgenetic alopecia is strong. Pyrilutamide and GT20029 are being studied as topical antagonists of the androgen receptor, while cetirizine is another topical option with some initial promising results.

2023年7月17日 · GT-20029 is a novel topical drug that targets androgen receptors. Developed by Kintor Pharmaceutical, the same company responsible for the development of Pyrilutamide, GT-20029 is designed as a treatment for androgenetic alopecia (AGA) and Acne vulgaris.

GT20029 is a topical AR-Proteolysis Targeting Chimera (PROTAC) owned by Kintor Pharma. In preclinical studies, by degrading AR protein, GT20029 could block the shrinkage and miniaturization of hair follicles which was caused by the activation of AR signaling pathway. As the result, it prevented the hair from thinning, softening and falling out.

2024年4月22日 · Kintor Pharmaceutical just announced that its China Phase II clinical trial of its first-in-class androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound GT20029 for treating androgenetic alopecia has reached the primary endpoint.

2023年11月29日 · Two androgen receptor-targeting products: GT20029 (a degrader) and KX-826 (an antagonist), with trials in both China and the US for male and female androgenetic alopecia patients. This totals 24 different trial developments, with over half already completed.